Drug data last refreshed 8h ago · AI intelligence enriched 1w ago
VALTREX (valacyclovir hydrochloride) is an oral antiviral nucleoside analog prodrug used to treat herpes simplex virus (HSV) infections, varicella-zoster virus (VZV), and Epstein-Barr virus (EBV) infections. It is converted in the body to acyclovir, which inhibits viral DNA polymerase to prevent viral replication. The drug is indicated for treatment and suppression of genital herpes, cold sores, and shingles.
As LOE approaches, brand teams are transitioning focus from volume growth to managed decline and cost optimization, with smaller core teams maintaining legacy assets.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Special Drug Use Investigation for VALTREX (Valaciclovir) (Pediatrics Chickenpox)
Special Drug Use Investigation for VALTREX (Valaciclovir) (Suppression Prophylaxis)
VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2
Fed Study of Valacyclovir Hydrochloride Tablets 1000 mg and Valtrex® Tablets 1000 mg
Fasting Study of Valacyclovir Hydrochloride Tablets 1000 mg and Valtrex® Tablets 1000 mg
Worked on VALTREX at GSK? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on VALTREX offers limited growth trajectory but provides valuable experience in mature brand management, generic competition mitigation, and lifecycle extension strategies. Career development on this product is best suited for professionals seeking stability and mastery of post-LOE portfolio stewardship rather than launch-phase visibility or rapid growth.